Plk1-Targeted small molecule inhibitors: Molecular basis for their potency and specificity

Molecules and Cells

Volumn 32, Issue 3, 2011, Pages 209-220

  Ravichandran N Murugan, ^a   Park, Jung Eun ^b   Kim, Eun Hee ^a   Shin, Song Yub ^c   Cheong, Chaejoon ^a   Lee, Kyung S ^b   Bang, Jeong Kyu ^a  

^a Korea Basic Science Institute (KBSI)   (South Korea)

^b NATIONAL CANCER INSTITUTE   (United States)

^c Chosun University College of Medicine   (South Korea)

Author keywords

Cancer therapy; Inhibitors; Plk1; Polo box domain (PBD); Polo like kinase

Indexed keywords

4 (8 CYCLOPENTYL 7 ETHYL 5,6,7,8 TETRAHYDRO 5 METHYL 6 OXO 2 PTERIDINYLAMINO) 3 METHOXY N (1 METHYL 4 PIPERIDINYL)BENZAMIDE; CYC 800; DOXORUBICIN; GSK 461364A; HMN 214; IRINOTECAN; LLCSPTPNG PEPTIDE; MAGPMQSPTPLNGAKK PEPTIDE; MQSPTPL PEPTIDE; NMS 1; OXALIPLATIN; PACLITAXEL; PHOSPHOPEPTIDE; PLHSPT PEPTIDE; POLO LIKE KINASE 1; POLO LIKE KINASE 1 INHIBITOR; POLO LIKE KINASE INHIBITOR; POLOXIN; POLOXIPAN; PURPUROGALLIN; RIGOSERTIB; SBE 13; SCYTONEMIN; SMALL MOLECULE INHIBITOR; THYMOQUINONE; UNCLASSIFIED DRUG; VINCRISTINE; VOLASERTIB; WORTMANNIN;

AMINO TERMINAL SEQUENCE; BRAIN METASTASIS; BREAST CANCER; CARBOXY TERMINAL SEQUENCE; CARCINOMA; COLON CANCER; COLORECTAL CANCER; DRUG DOSE ESCALATION; DRUG EFFECT; DRUG MECHANISM; DRUG POTENCY; DRUG SPECIFICITY; DRUG TARGETING; ENZYME ACTIVITY; HUMAN; LUNG CANCER; LUNG NON SMALL CELL CANCER; LUNG SMALL CELL CANCER; METASTASIS; NONHODGKIN LYMPHOMA; NONHUMAN; PANCREAS CANCER; PROSTATE CANCER; PROTEIN DOMAIN; REVIEW; SOLID TUMOR; STOMACH CANCER;

ANTINEOPLASTIC AGENTS; BINDING SITES; CATALYTIC DOMAIN; CELL CYCLE PROTEINS; CELL PROLIFERATION; CELL TRANSFORMATION, NEOPLASTIC; DRUG DESIGN; GENE EXPRESSION REGULATION, NEOPLASTIC; HIGH-THROUGHPUT SCREENING ASSAYS; HUMANS; MODELS, MOLECULAR; MOLECULAR TARGETED THERAPY; NEOPLASMS; PROTEIN BINDING; PROTEIN KINASE INHIBITORS; PROTEIN STRUCTURE, TERTIARY; PROTEIN-SERINE-THREONINE KINASES; PROTO-ONCOGENE PROTEINS; SMALL MOLECULE LIBRARIES; SUBSTRATE SPECIFICITY;

EUKARYOTA;

EID: 84855676685     PISSN: 10168478     EISSN: 02191032     Source Type: Journal    
DOI: 10.1007/s10059-011-0126-3     Document Type: Review

References (73)

1. Archambault, V., and Glover, D.M. (2009). Polo-like kinases: Conservation and divergence in their functions and regulation. Nat. Rev. Mol. Cell Biol. 10, 265-275.
2. Bandeiras, T.M., Hillig, R.C., Matias, P.M., Eberspaecher, U., Fanghanel, J., Thomaz, M., Miranda, S., Crusius, K., Putter, V., Amstutz, P., et al. (2008). Structure of wild-type Plk1 kinase domain in complex with a selective DARPin. Acta Cryst. D64, 339-353. (Pubitemid 351507797)
3. Barr, F., Sillje, H., and Nigg, E. (2004). Polo-like kinases and the orchestration of cell division. Nat. Rev. Mol. Cell Biol. 5, 429-440. (Pubitemid 38745493)
4. Beria, I., Valsasina, B., Brasca, M.G., Caruso, M., Ferguson, R.R., Lansen, J., Moll, J., Pesenti, E., Posteri, H., and Rocchetti, M. (2008). Antitumoral activity of pyrazoloquinazoline derivatives as potent oral Plk1 specific inhibitors. Eur. J Cancer 6, 136.
5. Beria, I., Ballinari, D., Bertrand, J.A., Borghi, D., Bossi, R.T., Brasca, M.G., Ferguson, R.D., Lansen, J., Rocchetti, M., Storici, M., et al. (2010). Identification of 4,5-Dihydro-1H-pyrazolo[4,3-h]quinazoline derivatives as a new class of orally and selective Polo-like kinase 1inhibitors. J. Med. Chem. 53, 3532-3551.
6. Cheng, K.Y., Lowe, E.D., Sinclair, J., Nigg, E.A., and Johnson, L.N. (2003). The crystal structure of the human polo-like kinase 1 polo box domain and its phosphor-peptide complex. EMBO J. 22, 5757-5768. (Pubitemid 37408815)
7. Eckerdt, F., Yuan, J., and Strebhardt, K. (2005). Polo-like kinases and oncogenesis. Oncogene 24, 267-276. (Pubitemid 40188607)
8. Elez, R., Piiper, A., Kronenberger, B., Kock, M., Brendel, M., Hermann, E., Pliquett, U., Neumann., E., and Zeuzem, S. (2003). Tumor regression by combination antisense therapy against Plk1 and Bcl-2. Oncogene 22, 69-80. (Pubitemid 36152885)
9. Elia, A.E., Rellos, P., Haire, L.F., Chao, J.W., Ivins, F.J., Hoepker, K., Mohammad, D., Cantley, L.C., Smerdon, S.J., and Yaffe, M.B. (2003a). The molecular basis for phosphodependent substrate targeting and regulation of Plks by the Polo-box domain. Cell 115, 83-95. (Pubitemid 37255320)
10. Elia, A.E., Cantley, L.C., and Yaffe, M.B. (2003b). Proteomic screen finds pSer/pThr binding domain localizing Plk1 to mitotic substrates. Science 299, 1228-1231. (Pubitemid 36237463)
11. Elling, R.A., Fucini, R.V., and Romanowski, M.J. (2008a). Structures of the wild-type and activated catalytic domains of Brachydanio rerio Polo-like kinase 1 (Plk1): Changes in the active-site conformation and interactions with ligands. Acta Cryst. D64, 909-918.
12. Elling, R.A., Fucini, R.V., Hanan, E.J., Barr, K.J., Zhu, J., Paulvannan, K., Yang, W., and Romanowski, M.J. (2008b). Structure of the Brachydanio rerio Polo-like kinase 1 (Plk1) catalytic domain in complex with an extended inhibitor targeting the adaptive pocket of the enzyme. Acta Cryst. F64, 686-691.
13. Emmitte, K.A., Adjebang, G.M., Andrews, C.W., Badiang, J.G., Bambal, R., Chamberlain, S.D., Davis-Ward, R.G., Dickson, H.D., Hassler, D.F., Hornberger, K.R., et al. (2009). Design of potent thiophene inhibitors of polo-like kinase 1 with improved solubility and reduced protein binding. Bioorg. Med. Chem. Lett. 19, 1694-1697.
14. Erskine, S., Madden, L., Hassler, D., Smith, G., Copeland, R., and Gontarek, R. (2007). Biochemical characterization of GSK461364A: A novel, potent, and selective inhibitor of Polo-like kinase 1 (Plk1). Presented at the 98th American Association for Cancer Research Annual Meeting, Los Angeles, April 14-18.
15. Fucini, R.V., Hanan, E.J., Romanowski, M.J., Elling, R.A., Lew, W., Barr, K.J., Zhu, J., Yoburn, J.C., Liu, Y., Fahr, B.T., et al. (2008). Design and synthesis of 2-amino-pyrazolopyridines as Polo-like kinase 1 inhibitors. Bioorg. Med. Chem. Lett. 18, 5648-5652.
16. Gandhi, L., Chu, Q.S., Stephenson, J., Johnson, B.E., Govindan, R., Bonomi, P., Eaton, K., Fritsch, H., Munzert, G., and Socinski, M. (2009). An open label phase II trial of the Plk1 inhibitor BI 2536, in patients with sensitive relapsed small cell lung cancer (SCLC). J. Clin. Oncol. 27, 8108.
17. Garcia-Alvarez, B., de Carcer, G., Ibanez, S., Bragado-Nilsson, E., and Montoya, G. (2007). Molecular and structural basis of pololike kinase 1 substrate recognition: Implications in centrosomal localization. Proc. Natl. Acad. Sci. USA 104, 3107-3112. (Pubitemid 46364121)
18. Garland, L.L., Taylor, C., Pilkington, D.L. Cohen, J.L., and Von Hoff, D.D. (2006). A phase I pharmacokinetic study of HMN-214, a novel oral stilbene derivative with polo-like kinase 1 interacting properties, in patients with advanced solid tumors. Clin. Cancer Res. 12, 5182-5189. (Pubitemid 44453347)
19. Gilmartin, A.G., Bleam, M.R., Richter, M.C., Erskine, S.G., Kruger, R.G., Madden, L., Hassler, D.F., Smith, G.K., Gontarek, R.R., Courtney, M.P., et al. (2009). Distinct concentration-dependent effects of the polo-like kinase 1 specific inhibitor GSK461364A, including differential effect on apoptosis. Cancer Res. 69, 6969-6977.
20. Gleixner, K., Ferenc, V., Peter, B., Gruze, A., Meyer, R., Hadzijusufovic., Cerny-Reiterer, S., Mayerhofer, M., Pickl, W.F., Valent, P., et al. (2010). Polo-like kinase 1 (Plk1) as a novel drug target in chronic myeloid leukemia: Overriding imatinib resistance with the Plk1 inhibitor BI 2536. Cancer Res. 15, 1513.
21. Gumireddy, K., Reddy, M.V., Cosenza, S.C., Boominathan, R., Baker, S.J., Papathi, N., Jiang, J., Holland, J., and Reddy, E.P. (2005). ON01910, a non-ATP-competitive small molecule inhibitor of Plk1, is a potent anticancer agent. Cancer Cell 7, 275-286. (Pubitemid 40568686)
22. Hanan, E.J., Fucini, R.V., Romanowski, M.J., Elling, R.A., Lew, W., Purkey, H.E., Vanderporten, E.C., and Yang, W. (2008). Design and synthesis of 2-amino-isoxazolopyridines as Polo-like kinase inhibitors. Bioorg. Med. Chem. Lett. 18, 5186-5189.
23. Johnson, E.F., Stewart, K.D., Woods, K.W., Giranda, V.L., and Luo, Y. (2007). Pharmacological and functional comparison of the Polo-like kinase family: Insight into inhibitor and substrate specificity. Biochemistry 46, 9551-9563. (Pubitemid 47291962)
24. Kang, Y.H., Park, J.E., Yu, L.R., Soung, N.K., Yun, S.M., Bang, J.K., Seong, Y.S., Yu, H., Garfield, S., Veenstra, T.D., et al. (2006). Self-regulated Plk1 recruitment to kinetochores by the Plk1-PBIP1 interaction is critical for proper chromosome segregation. Mol. Cell 24, 409-422. (Pubitemid 44754942)
25. Karaman, M.W., Herrgard, S., Treiber, D.K., Gallant, P., Atteridge, C.E., Campbell, B.T., Chan, K.W., Ciceri, P., Davis, M.I., Edeen, P.T., et al. (2008). A quantitative analysis of kinase inhibitor selectivity. Nat. Biotechnol. 26, 127-132.
26. Keppner, S., Proschak, E., Schneider, G., and Spankuch, B. (2009). Identification and validation of a potent type II inhibitor of inactive Polo-like kinase 1. Chem. Med. Chem. 4, 1806-1809.
27. Knecht, R., Elez, R., Oechler, M., Solbach, C., von Ilberg, C., and Strebhardt, K. (1999). Prognostic significance of polo-like kinase (PLK) expression in squamous cell carcinomas of the head and neck. Cancer Res. 59, 2794-2797. (Pubitemid 29283110)
28. Knecht, R., Oberhauser, C., and Strebhardt, K. (2000). PLK (pololike kinase), a new prognostic marker for oropharyngeal carcinomas. Int. J. Cancer 89, 535-536.
29. Kneisel, L., Strebhardt, K., Bernd, A., Wolter, M., Binder, A., and Kaufmann, R. (2002). Expression of polo-like kinase (PLK1) in thin melanomas: A novel marker of metastatic disease. J. Cutan. Pathol. 29, 354-358.
30. Kops, G.J., Weaver, B.A., and Cleveland, D.W. (2005). On the road to cancer: Aneuploidy and the mitotic checkpoint. Nat. Rev. Cancer 5, 773-785. (Pubitemid 41400777)
31. Kothe, M., Kohls, D., Low, S., Coli, R., Cheng, A.C., Jacques, S.L., Johnson, T.L., Lewis, C., Loh, C., Ding, Y-H., et al. (2007a). Structure of the catalytic domain of human polo-like kinase 1. Biochemistry 46, 5960-5971. (Pubitemid 46799158)
32. Kothe, M., Kohls, D., Low, S., Coli, R., Rennie, G.R., Feru, F., Kuhn, C., and Ding, Y-H. (2007b). Selectivity-determining residues in Plk1. Chem. Biol. Drug Dis. 70, 540-546. (Pubitemid 350150876)
33. Laquerre, S., Sung, S.-M., Gilmartin, A., Courtney, M., Ho, M., Salovich, J., Cheung, M., Kuntz, K., Huang, P., and Jackson, J. (2007). A potent and selective Polo-like kinase 1 (Plk1) inhibitor (GSK461364A) induces cell cycle arrest and growth inhibition of cancer cell. Presented at the 98th American Association for Cancer Research Annual Meeting, Los Angeles, April 14-18.
34. Lee, K.S., Grenfell, T.Z., Yarm, F.R., and Erikson, R.L. (1998). Mutation of the polo-box disrupts localization and mitotic functions of the mammalian Polo like kinase. Proc. Natl. Acad. Sci. USA 95, 9301-9306. (Pubitemid 28506226)
35. Lenart, P., Petronczki, M., Steegmaier, M., Di Fiore, B., Lipp, J.J., Hoffmann, M., Rettig, W.J., Kraut, N., and Peters, J.M. (2007). The small-molecule inhibitor BI 2536 reveals novel insights into mitotic roles of polo-like kinase 1. Curr. Biol. 17, 304-315.
36. Leung, G.C., Hudson, J.W., Kozarova, A., Davidson, A., Dennis, J.W., and Sicheri, F. (2002). The Sak Polo-box comprises a structural domain sufficient for mitotic subcellular localization. Nat. Struct. Biol. 9, 719-724.
37. Liao, J.J.-L. (2007). Molecular recognition of protein kinase binding pockets for design of potent and selective kinase inhibitors. J. Med. Chem. 50, 409-424. (Pubitemid 46239775)
38. Liao, C., Park, J.E., Bang, J.K., Nicklaus, M.C., and Lee, K.S. (2010). Probing binding modes of small molecule inhibitors to the Polo-box domain of human Polo-like kinase. ACS Med. Chem. Lett. 1, 110-114.
39. Liu, Y., and Gray, N.S. (2006). Rational design of inhibitors that bind to inactive kinase conformations. Nat. Chem. Biol. 2, 358-364. (Pubitemid 43936934)
40. Liu, Y., Shreder, K.R., Gai, W., Corral, S., Ferris, D.K., and Rosenblum., J.S. (2005). Wortmannin, a widely used phosphoinositide 3-kinase inhibitor, also potently inhibits mammalian polo like kinase. Chem. Biol. 12, 99-107. (Pubitemid 40118330)
41. Liu, X., Lei, M., and Erikson, R.L. (2006). Normal cells, but not cancer cells, survive Plk1 depletion. Mol. Cell. Biol. 26, 2093-2108. (Pubitemid 43346913)
42. Luo, J., Emanuele, M.J., Li, D., Creighton, C.J., Schlabach, M.R., Westbrook, T.F., Wong, K-K., and Elledge, S.J. (2009). A Genome-wide RNAi screen identifies multiple synthetic lethal interactions with the Ras oncogene. Cell 137, 835-848.
43. McInnes, C., Mezna, M., and Fishcher, P.M. (2005). Progress in the discovery of polo-like kinase inhibitors. Curr. Top. Med. Chem. 5, 181-197. (Pubitemid 40514514)
44. McInnes, C., Mazumdar, A., Mezna, M., Meades, C., Midgley, C., Scaerou, F., Carpenter, L., Mackenzie, M., Taylor, P., Glover, D., et al. (2006). Inhibitors of Polo-like kinase reveal roles in spindlepole maintenance. Nat. Chem. Biol. 2, 608-617. (Pubitemid 44610345)
45. Mross, K., Frost, A., Steinbild, S., Hedbom, S., Rentschler, J., Kaiser, R., Rouyrre, N., Trommeshauser, D., Hoesl, C.E., and Munzert, G. (2008). Phase I dose escalation and pharmacokinetic study of BI 2536, a novel polo-like kinase 1 inhibitor, in patients with advanced solid tumors. J. Clin. Oncol. 26, 5511-5517.
46. Olmos, D., Allred, A., Sharma, R., Brunetto, A., Smith, D., Murray, S., Barker, D., Taegtmeyer, A., de Bono, J., and Blagden, S. (2009). Phase I first-in-human study of the polo-like kinase 1 selective inhibitor, GSK461364A, in patients with advanced solid tumors. J. Clin. Oncol. 27, 3536.
47. Palmieri, D., Hau, E., and Qian, Y. (2009). Preclinical studies investigating the efficacy of GSK461364A, an inhibitor of Polo-like kinase 1, for the prevention of breast cancer brain meta-stases. Presented at the American Association for Cancer Research, Denver, April 18-22.
48. Pandha, H.S., Protheroe, A., Wylie, J., Parker, C., Chambers, J., Bell, S., and Munzert, G. (2008). An open label phase II trial of BI 2536, a novel Plk1 inhibitor, in patients with metastatic hormone refractory prostate cancer (HRPC). J. Clin. Oncol. 26, 14547.
49. Park, J.-E., Soung, N.-K., Johmura, Y., Kang, Y.H., Liao, C., Lee, K.H., Park, C.H., Nicklaus, M.C., and Lee, K.S. (2010). Polo-box domain: A versatile mediator of polo-like kinase function. Cell. Mol. Life Sci. 67, 1957-1970.
50. Peters, U., Cherian, J., Kim, J.H., Kwok, B.H., and Kapoor, T.M. (2006). Probing cell-division phenotype space and Polo-like kinase function using small molecules. Nat. Chem. Biol. 2, 618-626. (Pubitemid 44610346)
51. Petronczki, M., Lenart, P., and Peters, J.-M. (2008). Polo on the risefrom mitotic entry to cytokinesis with Plk1. Dev. Cell 14, 646-659. (Pubitemid 351622626)
52. Reindl, W., Yuan, J., Kramer, A., Strebhardt, K., and Berg, T. (2008). Inhibition of polo-like kinase 1 by blocking polo-box domaindependent protein-protein interactions. Chem. Biol. 15, 459-466. (Pubitemid 351645109)
53. Reindl, W., Yuan, J., Kramer, A., Strebhardt, T., and Berg, T. (2009). A pan-specific inhibitor of the polo-box domains of polo-like kinases arrests cancer cells in mitosis. Chembiochem. 10, 1145-1148.
54. Rudolph, D., Steegmaier, M., Grauert, M., Baum, A., Quant, J., Garin-Chesa, P., and Adolf, G.R. (2008). Characterization of BI 6727, a novel Polo-like kinase inhibitor with a distinct pharmacokinetic profile and efficacy in a model of taxane-resistant colon cancer. 20th EORTC-NCI-American Association for Cancer Research Symposium on Molecular Targets and Cancer Therapeutics, Oct. 21-24, 430.
55. Rudolph, D., Steegmaier, M., Hoffmann, M., Grauert, M., Baum, A., Quant, J., Haslinger, C., Garin-Chesa, P., and Adolf, G.R. (2009). BI 6727, a Polo-like kinase inhibitor with improved pharmacokinetic profile and broad antitumor activity. Clin. Cancer Res. 15, 3094-3102.
56. Santamaria, A., Neef, R., Eberspacher, U., Eis, K., Husemann, M., Mumberg, D., Prechtl, S., Schulze, V., Siemeister, G., Wortmann, L., et al. (2007). Use of the novel Plk1 inhibitor ZKthiazolidinone to elucidate functions of Plk1 in early and late stages of mitosis. Mol. Biol. Cell 18, 4024-4036. (Pubitemid 47519493)
57. Sato, Y., Onozaki, Y., Sugimoto, T., Kurihara, H., Kamijo, K., Kadowaki, C., Tsujino, T., Watanabe, A., Otsuki, S., Mitsuya, M., et al. (2009). Imidazopyridine derivatives as potent and selective Pololike kinase inhibitors. Bioorg. Med. Chem. Lett. 19, 4673-4678.
58. Schoffski, P., Awada, A., Dumez, H., Gil, T., Bartholomeus, S., Selleslach, J., Taton, M., Fritsch, H., Peter, N., and Munzert, G. (2008). A Phase I single dose escalation study of the novel Polo-like kinase 1 inhibitor BI 6727 in patients with advanced solid tumors. Eur. J. Cancer 6, 14-15.
59. Steegmaier, M., Hoffmann, M., Baum, A., Lenart, P., Petronczki, M., Krssak, M., Gurtler, U., Garin-Chesa, P., Lieb, S., Kraut, N., et al. (2007). BI 2536, a potent and selective inhibitor of polo-like kinase 1, inhibits tumor growth in vivo. Curr. Biol. 17, 316-322. (Pubitemid 46241881)
60. Stevenson, C.S., Capper, E.A., Roshak, A.K., Marquez, B., Eichman, C., Jackson, J.R., Mattern, M., Gerwick, W.H., Jacobs, R.S., and Marshall, L.A. (2002). The identification and characterization of the marine natural product scytonemin as a novel antiproliferative pharmacophore. J. Pharmacol. Exp. Ther. 303, 858-866. (Pubitemid 35231263)
61. Strebhardt, K. (2010). Multifaceted polo-like kinases: Drug targets and antitargets for cancer therapy. Nat. Rev. Drug Discov. 9, 643-660.
62. Strebhardt, K., and Ullrich, A. (2006). Targeting polo-like kinase 1 for cancer therapy. Nat. Rev. Cancer 6, 321-330.
63. Sur, S., Pagliarini, R., Bunz, F., Rago, C., Diaz, L.A. Jr., Kinler, K.W., Vogelstein, B., and Papadopoulos, N. (2009). A panel of isogenic human cancer cells suggests a therapeutic approach for cancers with inactivated p53. Proc. Natl. Acad. Sci. USA 106, 3964-3969.
64. Takagi, M., Honmura, T., Watanabe, S., Yamaguchi, R., Nogawa, M., Nishimura, I., Katoh, F., Matsuda, M., and Hidaka, H. (2003). In vivo antitumor activity of a novel sulfonamide, HMN-214, against human tumor xenografts in mice and the spectrum of cytotoxicity of its active metabolite, HMN-176. Invest. New Drugs 21, 387-399. (Pubitemid 38124978)
65. Takai, N., Hamanaka, R., Yoshimatsu, J., and Miyakawa, I. (2005). Polo-like kinases (Plks) and cancer. Oncogene 24, 287-291. (Pubitemid 40188609)
66. Takakai, T., Trenz, K., Costanzo, V., and Petronczki, M. (2008). Polo-like kinase 1 reaches beyond mitosis-cytokinesis, DNA damage response, and development. Curr. Opin. Cell Biol. 20, 650-660.
67. Tanaka, H., Ohshima, N., Ikenoya, M., Komori, K., Katoh, F., and Hidaka, H. (2003). HMN-176, an active metabolite of the synthetic antitumor agent HMN-214, restores chemosensitivity to multidrug-resistant cells by targeting the transcription factor NFY. Cancer Res. 63, 6942-6947. (Pubitemid 37322980)
68. Van de Weerdt, B.C., and Medema, R.H. (2006). Polo-like kinases: A team in control of the division. Cell Cycle 5, 853-864. (Pubitemid 44145580)
69. Von Pawel, J., Reck, M., Digel, W., Kortsik, C., Thomas, M., Frickhofen, N., Schuler, M., Gaschler-Markefski, B., Hanft, G., and Sebastian, M. (2008). Randomized phase II trial of two dosing schedules of BI 2536, a novel Plk1 inhibitor, in patients with relapsed advanced or metastatic non-small cell lung cancer (NSCLC). J. Clin. Oncol. 26, 8030.
70. Vose, J., Young, A., Friedberg, J.W., Waller, E.K., Cheson, B.D., Trommeshauser, D., and Munzert, G. (2008). Phase I doseescalation trial of BI 2536, a polo-like kinase 1 inhibitor, in relapsed and refractory Non-Hodgkin's lymphoma. Blood 112, 233.
71. Watanabe, N., Sekine, T., Takagi, M., Iwasaki, J., Imamoto, N., Kawasaki, H., and Osada, H. (2009). Deficiency in chromosome congression by the inhibition of Plk1 polo box domaindependent recognition. 284, 2344-2353.
72. Yuan, J., Horlin, A., Hock, B., Stutte, H.J., Rubsamen-Waigmann, H., and Strebhardt, K. (1997). Polo-like kinase, a novel marker for cellular proliferation. Am. J. Pathol. 150, 1165-1172. (Pubitemid 27152634)
73. Yun, S.M., Moulaei, T., Lim, D., Bang, J.K., Park, J.E., Shenoy, S. R., Liu, F., Kang, Y.H., Liao, C., Soung, N.K., et al. (2009). Structural and functional analyses of minimal phosphopeptides targeting the polo-box domain of polo-like kinase 1. Nat. Struct. Mol. Biol. 16, 876-882.